...
search icon
lxrx-img

Lexicon Pharmaceuticals Inc Share Price

LXRX
NAQ
$1.705
+$0
(0%)
1D
Industry: Biotechnology Sector: Health Care

Lexicon Pharmaceuticals Inc Analyst Forecast

Lexicon Pharmaceuticals Inc Share Price Chart

Lexicon Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$714.55M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.25M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.32 L
$1.83 H
$1.705

About Lexicon Pharmaceuticals Inc, Common Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. more

Industry: BiotechnologySector: Health Care

Lexicon Pharmaceuticals Inc Stock Returns

Time FrameLXRXSectorS&P500
1-Week Return16.33%-4.68%-2%
1-Month Return39.02%-3.18%-2.65%
3-Month Return23.02%0.84%-1.62%
6-Month Return58.33%10.77%3.68%
1-Year Return365.05%2.3%17.42%
3-Year Return-34.23%18.27%66.37%
5-Year Return-74.61%35.44%76.21%
10-Year Return-85.4%124.72%236.14%

Lexicon Pharmaceuticals Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue298.00K139.00K1.20M31.08M49.80M[{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":0.28,"profit":true},{"date":"2023-12-31","value":2.42,"profit":true},{"date":"2024-12-31","value":62.41,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Cost of Revenue55.05M52.52M58.97M616.00K274.00K[{"date":"2021-12-31","value":93.34,"profit":true},{"date":"2022-12-31","value":89.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":1.04,"profit":true},{"date":"2025-12-31","value":0.46,"profit":true}]
Gross Profit(54.75M)(52.38M)(57.77M)30.46M49.53M[{"date":"2021-12-31","value":-110.54,"profit":false},{"date":"2022-12-31","value":-105.75,"profit":false},{"date":"2023-12-31","value":-116.63,"profit":false},{"date":"2024-12-31","value":61.51,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Margin(18371.81%)(37681.29%)(4798.01%)98.02%99.45%[{"date":"2021-12-31","value":-18473.45,"profit":false},{"date":"2022-12-31","value":-37889.75,"profit":false},{"date":"2023-12-31","value":-4824.55,"profit":false},{"date":"2024-12-31","value":98.56,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Expenses32.34M48.38M113.98M227.58M98.44M[{"date":"2021-12-31","value":14.21,"profit":true},{"date":"2022-12-31","value":21.26,"profit":true},{"date":"2023-12-31","value":50.08,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":43.25,"profit":true}]
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)[{"date":"2021-12-31","value":-8709000000,"profit":false},{"date":"2022-12-31","value":-10076000000,"profit":false},{"date":"2023-12-31","value":-17175000000,"profit":false},{"date":"2024-12-31","value":-19711700000,"profit":false},{"date":"2025-12-31","value":-4891100000,"profit":false}]
Total Non-Operating Income/Expense(1.34M)(2.37M)(7.93M)(6.57M)-[{"date":"2021-12-31","value":-133600000,"profit":false},{"date":"2022-12-31","value":-236800000,"profit":false},{"date":"2023-12-31","value":-793500000,"profit":false},{"date":"2024-12-31","value":-657200000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Pre-Tax Income(87.76M)(101.94M)(177.12M)(200.40M)(50.34M)[{"date":"2021-12-31","value":-8775800000,"profit":false},{"date":"2022-12-31","value":-10194400000,"profit":false},{"date":"2023-12-31","value":-17711900000,"profit":false},{"date":"2024-12-31","value":-20040300000,"profit":false},{"date":"2025-12-31","value":-5034100000,"profit":false}]
Income Taxes510.00K1.18M386.11K(200.40M)-[{"date":"2021-12-31","value":43.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.61,"profit":true},{"date":"2024-12-31","value":-16925.93,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(88.27M)(103.13M)(177.51M)--[{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(87.76M)(101.94M)(157.86M)(200.40M)-[{"date":"2021-12-31","value":-8775800000,"profit":false},{"date":"2022-12-31","value":-10194400000,"profit":false},{"date":"2023-12-31","value":-15785700000,"profit":false},{"date":"2024-12-31","value":-20040300000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(87.76M)(101.94M)(177.12M)(200.40M)(50.34M)[{"date":"2021-12-31","value":-8775800000,"profit":false},{"date":"2022-12-31","value":-10194400000,"profit":false},{"date":"2023-12-31","value":-17711900000,"profit":false},{"date":"2024-12-31","value":-20040300000,"profit":false},{"date":"2025-12-31","value":-5034100000,"profit":false}]
EPS (Diluted)(0.61)(0.61)(0.80)(0.64)(0.14)[{"date":"2021-12-31","value":-61,"profit":false},{"date":"2022-12-31","value":-61,"profit":false},{"date":"2023-12-31","value":-80,"profit":false},{"date":"2024-12-31","value":-64,"profit":false},{"date":"2025-12-31","value":-14,"profit":false}]

Lexicon Pharmaceuticals Inc Ratios

Lexicon Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

LXRX
Cash Ratio 4.61
Current Ratio 4.88
Quick Ratio 4.87

Lexicon Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LXRX
ROA (LTM) -12.94%
ROE (LTM) -45.92%

Lexicon Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LXRX
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Lexicon Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LXRX
Trailing PE NM
Forward PE NM
P/S (TTM) 9.67
P/B 5.67
Price/FCF NM
EV/R 8.80
EV/Ebitda 16.57
PEG NM

FAQs

What is Lexicon Pharmaceuticals Inc share price today?

Lexicon Pharmaceuticals Inc (LXRX) share price today is $1.705

Can Indians buy Lexicon Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Lexicon Pharmaceuticals Inc (LXRX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LXRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lexicon Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Lexicon Pharmaceuticals Inc (LXRX) via the Vested app. You can start investing in Lexicon Pharmaceuticals Inc (LXRX) with a minimum investment of $1.

How to invest in Lexicon Pharmaceuticals Inc shares from India?

You can invest in shares of Lexicon Pharmaceuticals Inc (LXRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in LXRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lexicon Pharmaceuticals Inc shares
What is Lexicon Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Lexicon Pharmaceuticals Inc (LXRX) is $1.83. The 52-week low price of Lexicon Pharmaceuticals Inc (LXRX) is $0.32.

What is Lexicon Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lexicon Pharmaceuticals Inc (LXRX) is

What is Lexicon Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lexicon Pharmaceuticals Inc (LXRX) is 5.67

What is Lexicon Pharmaceuticals Inc dividend yield?

The dividend yield of Lexicon Pharmaceuticals Inc (LXRX) is 0.00%

What is the Market Cap of Lexicon Pharmaceuticals Inc?

The market capitalization of Lexicon Pharmaceuticals Inc (LXRX) is $714.55M

What is Lexicon Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Lexicon Pharmaceuticals Inc is LXRX

How Can Investors Use Lexicon Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Lexicon Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Lexicon Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Lexicon Pharmaceuticals Inc shares for Indian investors?

When investing in Lexicon Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Lexicon Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Lexicon Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Lexicon Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Lexicon Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top